These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 2878079

  • 1. Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors.
    Pelton JT, Kazmierski W, Gulya K, Yamamura HI, Hruby VJ.
    J Med Chem; 1986 Nov; 29(11):2370-5. PubMed ID: 2878079
    [Abstract] [Full Text] [Related]

  • 2. The mu-opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) [but not D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP)] produces a nonopioid receptor-mediated increase in K+ conductance of rat locus ceruleus neurons.
    Chieng B, Connor M, Christie MJ.
    Mol Pharmacol; 1996 Sep; 50(3):650-5. PubMed ID: 8794906
    [Abstract] [Full Text] [Related]

  • 3. Design and synthesis of somatostatin analogues with topographical properties that lead to highly potent and specific mu opioid receptor antagonists with greatly reduced binding at somatostatin receptors.
    Kazmierski W, Wire WS, Lui GK, Knapp RJ, Shook JE, Burks TF, Yamamura HI, Hruby VJ.
    J Med Chem; 1988 Nov; 31(11):2170-7. PubMed ID: 2903246
    [Abstract] [Full Text] [Related]

  • 4. Synthesis of highly mu and delta opioid receptor selective peptides containing a photoaffinity group.
    Landis G, Lui G, Shook JE, Yamamura HI, Burks TF, Hruby VJ.
    J Med Chem; 1989 Mar; 32(3):638-43. PubMed ID: 2537426
    [Abstract] [Full Text] [Related]

  • 5. Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo.
    Kramer TH, Shook JE, Kazmierski W, Ayres EA, Wire WS, Hruby VJ, Burks TF.
    J Pharmacol Exp Ther; 1989 May; 249(2):544-51. PubMed ID: 2566679
    [Abstract] [Full Text] [Related]

  • 6. Cyclic somatostatin analogues as potent antagonists at mu-, but not delta- and kappa-opioid receptors mediating presynaptic inhibition of neurotransmitter release in the brain.
    Mulder AH, Wardeh G, Hogenboom F, Kazmierski W, Hruby VJ, Schoffelmeer AN.
    Eur J Pharmacol; 1991 Nov 19; 205(1):1-6. PubMed ID: 1687463
    [Abstract] [Full Text] [Related]

  • 7. H-D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2: a potent and selective antagonist opioid receptors.
    Gulya K, Lui GK, Pelton JT, Kazmierski W, Hruby VJ, Yamamura HI.
    NIDA Res Monogr; 1986 Nov 19; 75():209-12. PubMed ID: 2893264
    [Abstract] [Full Text] [Related]

  • 8. [3H]-[H-D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2] ([3H]CTOP), a potent and highly selective peptide for mu opioid receptors in rat brain.
    Hawkins KN, Knapp RJ, Lui GK, Gulya K, Kazmierski W, Wan YP, Pelton JT, Hruby VJ, Yamamura HI.
    J Pharmacol Exp Ther; 1989 Jan 19; 248(1):73-80. PubMed ID: 2563293
    [Abstract] [Full Text] [Related]

  • 9. Cyclic somatostatin octapeptide analogues with high affinity and selectivity toward mu opioid receptors.
    Gulya K, Pelton JT, Hruby VJ, Yamamura HI.
    Life Sci; 1986 Jun 16; 38(24):2221-9. PubMed ID: 2872570
    [Abstract] [Full Text] [Related]

  • 10. Conformationally restricted analogs of somatostatin with high mu-opiate receptor specificity.
    Pelton JT, Gulya K, Hruby VJ, Duckles SP, Yamamura HI.
    Proc Natl Acad Sci U S A; 1985 Jan 16; 82(1):236-9. PubMed ID: 2857488
    [Abstract] [Full Text] [Related]

  • 11. De novo design, synthesis, and pharmacology of alpha-melanocyte stimulating hormone analogues derived from somatostatin by a hybrid approach.
    Han G, Haskell-Luevano C, Kendall L, Bonner G, Hadley ME, Cone RD, Hruby VJ.
    J Med Chem; 2004 Mar 11; 47(6):1514-26. PubMed ID: 14998337
    [Abstract] [Full Text] [Related]

  • 12. Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
    Erchegyi J, Waser B, Schaer JC, Cescato R, Brazeau JF, Rivier J, Reubi JC.
    J Med Chem; 2003 Dec 18; 46(26):5597-605. PubMed ID: 14667214
    [Abstract] [Full Text] [Related]

  • 13. Superactive octapeptide somatostatin analogs containing tryptophan at position 1.
    Cai RZ, Karashima T, Guoth J, Szoke B, Olsen D, Schally AV.
    Proc Natl Acad Sci U S A; 1987 Apr 18; 84(8):2502-6. PubMed ID: 2882520
    [Abstract] [Full Text] [Related]

  • 14. Opioid receptor selectivity of beta-endorphin in vitro and in vivo: mu, delta and epsilon receptors.
    Shook JE, Kazmierski W, Wire WS, Lemcke PK, Hruby VJ, Burks TF.
    J Pharmacol Exp Ther; 1988 Sep 18; 246(3):1018-25. PubMed ID: 2843623
    [Abstract] [Full Text] [Related]

  • 15. Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8.
    Erchegyi J, Penke B, Simon L, Michaelson S, Wenger S, Waser B, Cescato R, Schaer JC, Reubi JC, Rivier J.
    J Med Chem; 2003 Dec 18; 46(26):5587-96. PubMed ID: 14667213
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Agonist properties of putative small-molecule somatostatin sst2 receptor-selective antagonists.
    Nunn C, Langenegger D, Hurth K, Schmidt K, Fehlmann D, Hoyer D.
    Eur J Pharmacol; 2003 Apr 04; 465(3):211-8. PubMed ID: 12681432
    [Abstract] [Full Text] [Related]

  • 20. Central effects of the potent and highly selective mu opioid antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) in mice.
    Gulya K, Kriván M, Nyolczas N, Sarnyai Z, Kovács GL.
    Eur J Pharmacol; 1988 Jun 10; 150(3):355-60. PubMed ID: 2901358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.